TELA Bio will reduce annual operating expenses by approximately $17.0 million through a targeted workforce reduction of approximately 20%. The initiative matters to investors because the company says it will preserve Capital for product sales and innovation, with the expected benefit of extending its cash runway into 2028.

Key Highlights

  • The company expects approximately $1.5 million in aggregate restructuring charges, primarily tied to severance and employee-related costs.
  • Roberto Cuca stepped down as chief financial officer and chief operating officer on August 31, 2026, with Heather Getz appointed principal financial officer.
  • The program combines a targeted workforce reduction with streamlined external resources while preserving Investment in product innovation and core growth priorities.

The program combines a targeted workforce reduction with streamlined external resources while preserving investment in product innovation and core growth priorities.

Workforce Reduction Carries $1.5 Million Charge

TELA Bio (NASDAQ: TELA) expects the initiative to produce approximately $17.0 million in annual operating-expense savings, driven in part by a workforce reduction of approximately 20%.

The company expects aggregate charges of approximately $1.5 million, primarily for severance and other employee-related costs. The estimates depend on assumptions, and TELA Bio said implementation could result in additional charges or cash expenditures.

CFO Transition and Cash Runway Target

Heather Getz was appointed principal financial officer. TELA Bio expects to enter a separation agreement with Cuca on the same terms as his existing employment agreement, with that agreement to be filed in the Quarterly Report for the quarter ended September 30, 2026.

The company said the broader efficiency program is intended to preserve its ability to invest in core growth priorities and product innovation. TELA Bio also expects the initiative to extend its cash runway into 2028.

Peers Moving on This News